CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Nanopharmaceutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Nanopharmaceutics Inc
K-2-8 2nd. Floor Kuchai Business Park
Jalan 1/127 Off Jalan Kuchai Lama
Phone: +60 379878688p:+60 379878688 KUALA LUMPUR, 58200  Malaysia Ticker: PLSHPLSH
Business Summary
Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company. The Company is developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. The Company is developing a clinical pipeline of oral, topical and injectable small molecule drug candidates to treat human cancer, central nervous system (CNS) disorders and infectious diseases. The pipeline includes 10 clinical-stage proprietary and partnered programs including Triapine, Ammonium Tetrathiomolybdate and Aza-TdC, targeting cancer; NanoBUP, PRX-3140, NP-18-2, and NP-18-3, targeting CNS; and Ramoplanin and NanoDOX, targeting infectious disease. Leveraging its expertise in nanoparticle and fine-particle formulations, the Company is focused on formulation development aimed at improving drug absorption and stability. Triapine is a synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/201812/31/2017YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer and Director NumanIjaz
Chief Financial Officer, Secretary, Treasurer and Director AlexanderBains

Business Names
Business Name
American Crypto Systems, Inc.
Digital Engineering Corporation
PLSH
9 additional Business Names available in full report.

General Information
Number of Employees: 50 (As of 3/30/2018)
Outstanding Shares: 174,000,000 (As of 3/31/2023)
Stock Exchange: OTC
Federal Tax Id: 300887308


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, January 4, 2024